Siemens Healthcare now has available the DCA Vantage Analyzer, a point-of-care (POC) diabetes patient management platform reporting glycosylated hemoglobin (HbA1c), microalbumin/creatinine and albumin-to-creatinine results for diabetes management.
The DCA Vantage Analyzer is programmed for monitoring a patient’s glycemic control and helps physicians to encourage patient compliance by delivering actionable test results during a patient visit. The system is used at the point of care reportedly with no sample or reagent preparation steps. This analyzer is both CLIA waived and NGSP certified for HbA1C tests, according to the manufacturer.
The new DCA Vantage Analyzer is designed to allow physicians to enter a patient ID via touchscreen or bar code and view the on-board printed reports and HbA1c patient trending graphs. They can also download the patient results to an external hospital information system. For testing sites that require compliance and control of decentralized testing, powerful features such as connectivity to LIS, operator ID entry, QC reminders, test lock-out, remote access, and adjustable correlation to reference methods are available. Other unique features include the ability to adjust correlation parameters in order to match reference assays or standardize results over multiple systems.